[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebrovascular-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebrovascular-function":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100624181","respiratory-muscle-training-to-improve-cerebrovascular-and-immune-function-100624181",false,"NCT07406295","Respiratory Muscle Training to Improve Cerebrovascular and Immune Function","Novel Respiratory Muscle Training for Improving Cerebrovascular Function and Immune Status in Adults With Obesity","Inclusion Criteria:\n\n* Body mass index greater than or equal to 30 kg\u002Fm2\n* Waist circumference greater or equal to 88 cm for females and greater than or equal to 102 cm for males\n\nExclusion Criteria:\n\n* Not weight stable (\\\u003C5% change in body mass over the past six months)\n* Overt cardiovascular, neurological, renal, liver, and\u002For metabolic illness (e.g., diabetes mellitus)\n* Current, or history of uncontrolled, Stage 2 hypertension (blood pressure \\>140 \u002F 90 mmHg; anti-hypertensive medications are permitted)\n* Diagnosed obstructive sleep apnea\n* Previous bariatric surgery\n* Diagnosis or signs (e.g., values below the lower limit of normal) of overt airway disease(s)\n* Current or recent (regular use within the past 6 months) use of tobacco or nicotine products (e.g., cigarettes, vaping)\n* Pregnant (self-reported and confirmed via urine pregnancy test), lactating (self-reported), or post-menopausal (self-reported) females\n* Prisoners\n\nPer the POWERbreathe® company:\n\n* Patients who have undergone recent abdominal surgery and those with abdominal hernia.\n* Asthma patients who have a very low symptom perception and suffer from frequent, severe exacerbations or with an abnormally low perception of dyspnea.\n* If a patient is suffering from a ruptured eardrum or any other condition of the ear.\n* Patients with marked elevated left ventricular end-diastolic volume and pressure.\n* Patients with worsening heart failure signs and symptoms after training. If an individual is suffering from a cold, sinusitis or respiratory tract infection, it is advised that they do not use the POWERbreathe device.","ALL","18 Years","45 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Millions of adults in America have too much body fat, resulting in obesity. Obesity is detrimental to health and causes disease. Obesity reduces brain health, which causes the brain to function less effectively. Additionally, a lack of exercise contributes to poorer brain health. Most individuals feel they do not have time to exercise. There is a need for a quicker type of training that improves brain health. Newly developed breathing exercises could be a time-efficient, cost-effective, and home-based practice to increase brain health. This practice acts as weightlifting for breathing muscles.\n\nThese new breathing exercises have already been shown to increase heart health. Heart health is linked to brain health; if an intervention helps the heart, it is likely to also help the brain. It is currently unknown if breathing training can improve brain health in younger adults with obesity. The investigators will utilize the same 8-week program shown to improve heart health. Testing will be conducted before and after the breathing training. The first part of the study will determine if breathing exercises help brain health.\n\nObesity also causes inflammation. This is measured via blood but affects the entire body. It is thought to cause some of the negative outcomes of obesity. By lowering inflammation, it is likely to improve overall health. Breathing exercises may reduce inflammation, but more research is required. The second part of this study will determine whether breathing exercises help reduce inflammation. This study will determine if brain health can be improved in adults with obesity. This could help 40% of American adults with obesity to live longer and healthier lives.",[27,28,29],"Obesity","Cerebrovascular Function","Immune Cells Activity",[31,32,33],"Transcranial Doppler","Inspiratory Muscle Strength Training","Cerebrovascular Reactivity","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-26","ACTUAL",{"date":40,"type":38},"2026-01-27",{"date":42,"type":21},"2028-05-01",{"name":44,"class":45},"Florida State University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":46},"100607902","phase-2-equol-and-vascular-function-in-women-with-chronic-kidney-disease-100607902","NCT07194590","Equol and Vascular Function in Women With Chronic Kidney Disease","Equol Supplementation for Improving Vascular Function in Postmenopausal Women With CKD","Inclusion Criteria:\n\n* Postmenopausal women\n* Aged ≥50 years\n* CKD stage 3 or 4 (eGFR with the CKD-EPI 2021 race-free equation: 15-59 mL\u002Fmin\u002F1.73m2; stable renal function in the past 3 months)\n* Low habitual intake of soy (soy-related food intake \\\u003C 2 times per week assessed by Soy-Specific Food Frequency Questionnaire)\n* Weight stable in the prior 3 months (\\\u003C2 kg weight change) and willing to remain weight stable throughout the study\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with advanced CKD requiring chronic dialysis\n* Uncontrolled hypertension in CKD group (BP \\>140\u002F90 mmHg)\n* Use of any hormone replacement therapy\n* Allergy and\u002For intolerance to soy or soy-based products\n* Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin values 2X upper limit of normal range (upper limit of normal range AST: 117 U\u002FL; ALT: 52 U\u002FL; total bilirubin: 1.3 mg\u002FdL)\n* History of breast cancer\n* Significant co-morbid conditions with a life expectancy of \\\u003C 1 year\n* Current tobacco or nicotine use or history of use in the last 12 months\n* History of kidney transplant\n* History of severe congestive heart failure (i.e., ejection fraction \\\u003C35%)\n* History of hospitalization within the last month\n* Immunosuppressant agents taken in the past 12 months\n* Known malignancy","FEMALE","50 Years",{"count":57,"type":21},74,[59],"PHASE2","The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH.\n\nEquol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the effect of 12 weeks of oral equol supplementation on vascular function in postmenopausal women with CKD.",[62,63,64,28,65],"Chronic Kidney Disease (Stage 3-4)","Vascular Function","Cognitive Functions","Blood Pressure",[67,68,69,70,63],"S-equol","Randomized Controlled Trial","Chronic Kidney Disease","Women's Health","2026-06-01",{"date":73,"type":38},"2026-06-02",{"date":75,"type":38},"2026-02-19",{"date":77,"type":21},"2030-11-30",{"name":79,"class":45},"University of Colorado, Denver"]